Halozyme Therapeutics Inc. (NASDAQ:HALO) went up by 5.94% from its latest closing price compared to the recent 1-year high of $56.40. The company’s stock price has collected 7.42% of gains in the last five trading sessions. Press Release reported on 06/01/21 that Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE(R) at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Is It Worth Investing in Halozyme Therapeutics Inc. (NASDAQ :HALO) Right Now?
Halozyme Therapeutics Inc. (NASDAQ:HALO) scored a price-to-earnings ratio above its average ratio, recording 36.89 x from its present earnings ratio. Plus, the 36-month beta value for HALO is at 1.47. Opinions of the stock are interesting as 10 analysts out of 12 who provided ratings for Halozyme Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $49.50, which is $10.68 above the current price. HALO currently public float of 133.91M and currently shorts hold a 5.12% ratio of that float. Today, the average trading volume of HALO was 1.04M shares.
HALO’s Market Performance
HALO stocks went up by 7.42% for the week, with a monthly drop of -2.25% and a quarterly performance of -5.27%, while its annual performance rate touched 79.21%. The volatility ratio for the week stands at 3.72% while the volatility levels for the past 30 days are set at 3.44% for Halozyme Therapeutics Inc.. The simple moving average for the period of the last 20 days is 0.97% for HALO stocks with a simple moving average of 4.83% for the last 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with SVB Leerink repeating the rating for HALO by listing it as a “Outperform.” The predicted price for HALO in the upcoming period, according to SVB Leerink is $56 based on the research report published on May 17th of the current year 2021.
Piper Sandler, on the other hand, stated in their research note that they expect to see HALO reach a price target of $48, previously predicting the price at $50. The rating they have provided for HALO stocks is “Neutral” according to the report published on May 11th, 2021.
The Benchmark Company gave a rating of “Buy” to HALO, setting the target price at $59 in the report published on January 21st of the current year.
HALO Trading at -5.90% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.03% of loss for the given period.
Volatility was left at 3.44%, however, over the last 30 days, the volatility rate increased by 3.72%, as shares sank -1.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.53% upper at present.
During the last 5 trading sessions, HALO rose by +7.42%, which changed the moving average for the period of 200-days by +49.37% in comparison to the 20-day moving average, which settled at $41.28. In addition, Halozyme Therapeutics Inc. saw -2.32% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at HALO starting from Torley Helen, who sale 50,000 shares at the price of $39.66 back on Jun 07. After this action, Torley Helen now owns 537,160 shares of Halozyme Therapeutics Inc., valued at $1,982,950 using the latest closing price.
Torley Helen, the President and CEO of Halozyme Therapeutics Inc., sale 50,000 shares at $43.02 during a trade that took place back on May 11, which means that Torley Helen is holding 537,160 shares at $2,151,099 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- +53.91 for the present operating margin
- +83.79 for the gross margin
The net margin for Halozyme Therapeutics Inc. stands at +48.24. The total capital return value is set at 27.67, while invested capital returns managed to touch 41.25. Equity return is now at value 154.10, with 25.10 for asset returns.
Based on Halozyme Therapeutics Inc. (HALO), the company’s capital structure generated 262.98 points at debt to equity in total, while total debt to capital is 72.45.
When we switch over and look at the enterprise to sales, we see a ratio of 22.69, with the company’s debt to enterprise value settled at 0.07. The receivables turnover for the company is 3.41 and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.32.